Kian Immune Cell, as a knowledge-based company, was established in 2020 and specializes in developing, producing, and delivering cutting-edge cellular therapies based on immune cells, hematopoietic cells, and genetically modified cells.
Our mission is to focus on research and development, introducing new strategies for immune cell production, cryopreservation, and medical application in collaboration with selected partners.
Our vision is to be a leading innovative immune cell company dedicated to improving patients’ lives.
For over a decade, we have successfully established one of the region’s first allogeneic Natural Killer (NK) cell banks, enabling rapid access to off-the-shelf NK cell therapies for patients in urgent need. In close collaboration with leading medical and research institutions — including the Royan Institute, Tehran University of Medical Sciences, and Iran University of Medical Sciences — we are translating cellular science into real clinical solutions.
During Phase I safety studies, we verified that multiple injections of our lead product, Nikogene®, an allogeneic NK cell therapy, are safe in patients with malignant brain tumors. We are now advancing toward a Phase II clinical trial to evaluate its efficacy. Alongside Nikogene®, our platform pipeline continues to expand, developing next-generation immune cell products including Nikcell (familial donor NK cell), Niktoraal (healthy expanded and activated NK cell), Nikord (cord blood–derived NK cell), and the Chemobiogram Kit — designed to broaden anti-tumor responses and identify the most effective chemotherapy regimens for cancer patients.